Description
While CC carriers show 2.55x greater odds of remission, the functional pathway linking this polymorphism to treatment efficacy is unknown. This mechanistic gap limits personalized treatment approaches and drug development targeting KCNK2.
Gap type: unexplained_observation Source paper: Support for the involvement of the KCNK2 gene in major depressive disorder and response to antidepressant treatment. (None, None, PMID:19741570)